New Queen's spin-in company to revolutionize cancer detection

July 23, 2012

The development of novel medical imaging techniques to revolutionise cancer detection and treatment will be the result of a new partnership announced today between Queen's University Belfast and Cirdan Imaging Ltd.

The research will focus on developing new imaging equipment using X-rays and near Infrared (NIR) Fluorescence to assist clinicians in the detection, diagnosis and .

Complete surgical removal of a tumour is vital for the patient, and one of the most important prognostic factors for survival. The new devices will be used in diagnostic procedures, as well as , to better discriminate between healthy and .

Cirdan Imaging's first new device will be an imaging tool developed to assist Radiologists to take a biopsy from a suspect lesion to help diagnose . This product is planned to be launched within the next 12 months.

Queen's University have taken an equity shareholding in Cirdan Imaging Ltd through its venture spin-out company QUBIS Ltd, representing their first ever company spin-in.

Dr. Hugh Cormican is CEO of Cirdan Imaging. His previous collaboration with QUBIS led to the creation of Andor Technology, the fastest growing company manufacturing high performance digital cameras in the world today, employing some 260 people in 16 offices worldwide.

Speaking about the new partnership, Dr Cormican said: "I am delighted to be working with QUBIS and Queen's University again, and I look forward to the collaborative efforts in developing new techniques. We know that speed of detection and treatment of cancer is critical to and we hope that through this new faster, more efficient technology, patient outcomes and survival will be improved.

"Queen's University is one of the world's leading research centres for , and with our collaboration we can help bring the benefits of that research to impact on patient's lives in considerably shorter timescales than occur elsewhere in the world. In business terms we anticipate that there is also the potential to be the next IPO (AIM stock exchange listing) for Northern Ireland in five years time."

QUBIS CEO, Frank Bryan, said: "QUBIS is delighted to be involved in supporting this research initiative which will help develop safer, more cost effective, user friendly and compact diagnostic tools for early, more accurate diagnosis of cancer globally. Research into cancer has predominately been on getting an improved understanding of the disease, or on new therapeutics. Cirdan Imaging is focused on developing more accurate detection tools for the clinicians to better diagnose and treat the cancer, an area which has lagged behind. The team in Cirdan have an impressive track record in imaging technology and we are excited to be involved in this project."

Explore further: Gamma imaging provides superior tumor detection for dense breasts

Related Stories

Gamma imaging provides superior tumor detection for dense breasts

June 6, 2011
A study revealed at SNM's 58th Annual Meeting is comparing the breast-tumor detection capabilities of two very different imaging technologies—breast-specific gamma imaging (BSGI), which provides functional images of ...

New imaging agent has an appetite for dangerous prostate tumors

December 8, 2011
Non-invasive imaging detects prostate cancer earlier than ever before, but can't accurately distinguish between malignant and benign disease. According to Lawson Health Research Institute's Drs. John Lewis and Len Luyt, a ...

Recommended for you

Breast cancer researchers find bacteria imbalance link

October 19, 2017
Researchers in the United States have uncovered differences in the bacterial composition of breast tissue of healthy women versus those with breast cancer.

New study reveals breast cancer cells recycle their own ammonia waste as fuel

October 19, 2017
Breast cancer cells recycle ammonia, a waste byproduct of cell metabolism, and use it as a source of nitrogen to fuel tumor growth, report scientists from Harvard Medical School in the journal Science.

US regulators approve 2nd gene therapy for blood cancer

October 19, 2017
U.S. regulators on Wednesday approved a second gene therapy for a blood cancer, a one-time, custom-made treatment for aggressive lymphoma in adults.

New findings explain how UV rays trigger skin cancer

October 18, 2017
Melanoma, a cancer of skin pigment cells called melanocytes, will strike an estimated 87,110 people in the U.S. in 2017, according to the Centers for Disease Control and Prevention. A fraction of those melanomas come from ...

Drug yields high response rates for lung cancer patients with harsh mutation

October 18, 2017
A targeted therapy resurrected by the Moon Shots Program at The University of Texas MD Anderson Cancer Center has produced unprecedented response rates among patients with metastatic non-small cell lung cancer that carries ...

Possible new immune therapy target in lung cancer

October 18, 2017
A study from Bern University Hospital in collaboration with the University of Bern shows that so-called perivascular-like cells from lung tumors behave abnormally. They not only inadequately support vascular structures, but ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.